CLINICAL_TRIALS
trial_result
· 2024-01-26
Clinical Trial Update: A Study to Explore Pamiparib Treatment in Epithelial Ovarian Cancer After Prior PARP Inhibitor Exposure [Phase 2]
Summary
A Phase 2 trial investigating pamiparib for epithelial ovarian cancer after prior PARP inhibitor exposure.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Zhejiang Cancer Hospital | Conditions: Epithelial Ovarian Cancer | Phase 2 | Status: UNKNOWN